BRAF mutations are associated with some histological types of papillary thyroid carcinoma
Top Cited Papers
- 19 January 2004
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 202 (2) , 247-251
- https://doi.org/10.1002/path.1511
Abstract
Mutations in the BRAF gene have recently been detected in a wide range of neoplastic lesions with a particularly high prevalence in melanoma and papillary thyroid carcinoma (PTC). The hot-spot mutation BRAFV599E is frequently detected in PTC (36–69%), in contrast to its absence in other benign or malignant thyroid lesions. In order to unravel whether there is any association between the occurrence of the BRAF mutation and the histological pattern of PTC, in this study a previous series of 50 PTCs was extended to 134 cases, including ten cases of PTC-related entities—hyalinizing trabecular tumour (HTT) and mucoepidermoid carcinoma (MEC). Using PCR/SSCP and sequencing, the BRAFV599E mutation was detected in 45 of the 124 PTCs (36%). No mutations were detected in any case of HTT and MEC. BRAFV599E was present in 75% of Warthin-like PTCs and 53% of conventional PTCs, whereas no BRAFV599E mutations were detected in any of the 32 cases of the follicular variant of PTC. BRAFV599E was also detected in 6 of 11 cases of the oncocytic variant of PTC that displayed a papillary or mixed follicular–papillary growth pattern and in none of the four oncocytic PTCs with a follicular growth pattern. A distinct mutation in BRAF (codon K600E) was detected in three cases of the follicular variant of PTC. This study has confirmed the high prevalence of BRAFV599E in PTC and has shown that the mutation is almost exclusively seen in PTC with a papillary or mixed follicular–papillary growth pattern, regardless of the cytological features of the neoplastic cells. The results support the existence of an oncocytic variant of PTC that should be separated from the oncocytic variant of follicular carcinoma and suggest that the follicular variant of PTC may be genetically different from conventional PTC. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
Funding Information
- Fundação para a Ciência e Tecnologia POCTI/FEDER (POCTI/ESP/43631/99)
This publication has 19 references indexed in Scilit:
- BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTCOncogene, 2003
- BRAF Mutation in Papillary Thyroid CarcinomaJNCI Journal of the National Cancer Institute, 2003
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Signaling Networks That Link Cell Proliferation and Cell FateJournal of Biological Chemistry, 2002
- Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid CarcinomaThe American Journal of Pathology, 2002
- Molecular Basis of Hurthle Cell Papillary Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2000
- Endothelial apoptosis in Braf-deficient miceNature Genetics, 1997
- Recent Advances in Cytometry, Cytogenetics and Molecular Genetics of Thyroid Tumours and Tumour-like LesionsPathology - Research and Practice, 1995
- Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.Journal of Clinical Investigation, 1992